A5005617714- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Protein Degradation and Inhibitors
- Chronic Lymphocytic Leukemia Research
- Multiple Myeloma Research and Treatments
- Histone Deacetylase Inhibitors Research
- Lymphoma Diagnosis and Treatment
- interferon and immune responses
- Immune Cell Function and Interaction
- Viral Infectious Diseases and Gene Expression in Insects
- Retinoids in leukemia and cellular processes
- Biosimilars and Bioanalytical Methods
- Phytochemical compounds biological activities
- PI3K/AKT/mTOR signaling in cancer
- Cutaneous lymphoproliferative disorders research
- Cancer-related molecular mechanisms research
- RNA Interference and Gene Delivery
- RNA modifications and cancer
- Cancer-related gene regulation
- Cancer, Hypoxia, and Metabolism
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Genomics and Chromatin Dynamics
- RNA Research and Splicing
- Autophagy in Disease and Therapy
Ruijin Hospital
2017-2024
Shanghai Jiao Tong University
2016-2024
Shanghai Institute of Hematology
2016-2024
Multiple myeloma is a malignant plasma-cell disease, which highly dependent on the hypoxic bone marrow microenvironment. However, underlying mechanisms of hypoxia contributing to genesis are not fully understood. Here, we show that long non-coding RNA DARS-AS1 in directly upregulated by inducible factor (HIF)-1. Importantly, required for survival and tumorigenesis cells both vitro vivo. exerts its function binding RNA-binding motif protein 39 (RBM39), impedes interaction between RBM39 E3...
Abstract Despite the development of promising cancer therapeutic drugs, multiple myeloma (MM) remains an incurable disease. Bufalin is a bufanolide steroid compound traditional Chinese medicine Chan Su that was previously shown to exert growth suppression effects on cell lines. Previous studies conducted by our group demonstrated bufalin activated AKT/mTOR pathway in cells, which considered essential disease progression and related drug resistance MM. In view significant role AKT MM,...
Background Anti-CD19 chimeric antigen receptor T (CAR-T) cell therapy has proven effective for treating relapsed or refractory acute B leukemia. However, challenges such as cytokine release syndrome, dysfunction, and exhaustion persist. Enhancing CAR-T efficacy through changing CAR internalization recycling is a promising approach. The transmembrane domain the easiest motif to optimize modulating without introducing additional domains, its impact on not yet been thoroughly explored. In this...
Abstract Despite recent progress in the treatment, outcome of adult acute T-cell lymphoblastic leukemia (T-ALL) is poor. Development novel approach to combat this disease urgently required. Vorinostat, a pan-histone deacetylase (HDAC) inhibitor, exerts promising anticancer activity variety solid and hematologic malignancies. However, efficacy vorinostat monotherapy unsatisfactory. Here, we show that quinacrine (QC), an anti-malaria drug with potent autophagy inhibitory activity, could...
Abstract FLT3 internal tandem duplication (FLT3-ITD) mutations are one of the most prevalent somatic alterations associated with poor prognosis in patients acute myeloid leukemia (AML). The clinically approved kinase inhibitors gilteritinib and quizartinib improve survival AML FLT3-ITD mutations, but their long-term efficacy is limited by acquisition secondary drug-resistant mutations. In this study, we conducted virtual screening a library 60,411 small molecules identified foretinib as...
Proteasome inhibitor bortezomib has proven efficacy against multiple myeloma. However, activates the phosphatidylinositol 3-kinase/AKT (PI3K/AKT) pathway (which is essential to development of myeloma), often resulting in drug resistance and disease recurrence. The addition BKM120 significantly enhanced apoptotic effects both bortezomib-sensitive bortezomib-resistant cells. Treatment with alone increased phosphorylation AKT (P-AKT), whereas markedly downregulated P-AKT clinical relevance...
Abstract Diffuse large B‐cell lymphoma (DLBCL) is the most common lymphoid malignancy with a high relapse rate. We previously found that C‐X‐C motif chemokine receptor 4 (CXCR4) was highly expressed in DLBCL and associated poor prognosis. This study focused on effect of hypoxia‐inducible factor‐1α (HIF‐1α) CXCR4 expression progression. Two activated B cell‐like cell lines Ly‐3 SUDHL2 were transfected overexpression knockdown plasmids or HIF‐1α. The viability migration cells significantly...
The prognosis of acute myeloid leukemia (AML) is closely related to immune response changes. Further exploration the pathobiology AML focusing on immune-related genes would contribute development more advanced evaluation and treatment strategies. In this study, we established a novel immune-17 signature based transcriptome data from Cancer Genome Atlas (TCGA) Genotype-Tissue Expression (GTEx) databases. We found that biology processes transcriptional dysregulations are critical factors in...
<h2>Summary</h2> Internal tandem duplication mutations of the FMS-like tyrosine kinase-3 (FLT3-ITDs) occur in 25%–30% patients with acute myeloid leukemia (AML) and are associated dismal prognosis. Although FLT3 inhibitors have demonstrated initial clinical efficacy, overall outcome FLT3-ITD AML remains poor, highlighting urgency to develop more effective treatment strategies. In this study, we reveal that reduced protein stability anti-cancer p53, resulting drug resistance. Blocking p53...
<div>Abstract<p>FLT3 internal tandem duplication (FLT3-ITD) mutations are one of the most prevalent somatic alterations associated with poor prognosis in patients acute myeloid leukemia (AML). The clinically approved FLT3 kinase inhibitors gilteritinib and quizartinib improve survival AML FLT3-ITD mutations, but their long-term efficacy is limited by acquisition secondary drug-resistant mutations. In this study, we conducted virtual screening a library 60,411 small molecules...
<p>Supplementary Data</p>
<p>Table S2,S3,S4</p>
<p>Supplementary Data</p>
<div>Abstract<p>FLT3 internal tandem duplication (FLT3-ITD) mutations are one of the most prevalent somatic alterations associated with poor prognosis in patients acute myeloid leukemia (AML). The clinically approved FLT3 kinase inhibitors gilteritinib and quizartinib improve survival AML FLT3-ITD mutations, but their long-term efficacy is limited by acquisition secondary drug-resistant mutations. In this study, we conducted virtual screening a library 60,411 small molecules...
<p>Table S2,S3,S4</p>
Arsenic trioxide (ATO) has exhibited remarkable efficacy in treating acute promyelocytic leukemia (APL), primarily through promoting the degradation of PML-RARα fusion protein. However, ATO alone fails to confer any survival benefit non-APL myeloid (AML) patients and exhibits limited when used combination with other agents. Here, we explored general toxicity mechanisms APL potential drugs that could be combined exhibit synergistic lethal effects on AML. We demonstrated ROS upregulation were...
Although advancements in genomic and epigenetic research have deepened our understanding of acute myeloid leukemia (AML), only one-third patients can achieve durable remission. Growing evidence suggests that the immune microenvironment bone marrow influences prognosis survival AML. There is a specific association between CD8
The chemoresistance mechanism of diffuse large B-cell lymphoma (DLBCL) is still poorly understood, and patient prognosis remains unsatisfactory. This study aimed to investigate drug resistance mechanisms in non-germinal center B-cell-like (non-GCB) DLBCL.Doxorubicin (DOX)-resistant OCI-Ly3 cells were generated through long-term incubation a medium with gradually increasing DOX concentrations. expression levels genes related metabolism determined using functional gene grouping polymerase...
Abstract Purpose： Chimeric antigen receptor (CAR)-T cells against CD19 have been proven to be effective in treating B-cell hematological malignancies. However, the efficacy of this promising therapy is limited by many factors. Methods： In study, germinal center B-cell-like diffuse large lymphoma (GCB-DLBCL) cell line OCI-Ly1, and patient-derived xenografted (PDX) mice (CY-DLBCL) were used as CAR-T cell-resistant model. Meanwhile, activated (ABC) DLBCL OCI-Ly3 PDX (ZML-DLBCL) defined...